Major Depression Clinical Trial
— 2BSBOfficial title:
Modification of the Expression of ADARs and PDE8A Editing in Suicidal Behavior
Verified date | December 2021 |
Source | University Hospital, Montpellier |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Suicidal behavior (SB) is a major public health problem in France, with more than 10,000 suicides and 220,000 suicide attempts per year. According to the commonly accepted model for understanding suicidal behavior, individuals who carry a suicidal act when subjected to stress factors (environmental stress, depression, substance ...) are those which have a specific vulnerability. These vulnerabilities can be considered as clinical parameters (propensity to despair, aggressive and/or impulsive traits), neurobiological parameters (dysfunction of the serotonergic system, ...) and cognitive parameters (taking disadvantageous decision ...). Suicidal vulnerability is partly underpinned by genetic factors. The interest of current researches is to identify biomarkers that will improve the opportunities for early identification of subject with a risk for SB. Numerous scientific studies, including post-mortem studies of the brains of suicide completers, have established a link between dysregulation of the ribonucleic acids editing (RNA) of certain genes, the enzymatic activity of Adenosine deaminases acting on RNA (ADARS) responsible for this edition and suicidal behavior. A prospective study is needed to quantify and qualify in the blood of depressed patients (with or without a history of suicide) and healthy controls, the editing changes and the expression and alteration of the activity of ADARS.
Status | Completed |
Enrollment | 600 |
Est. completion date | June 24, 2020 |
Est. primary completion date | June 24, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | No specific inclusion criteria : - 18 to 65 years - Subject who signed the informed consent - Able to understand the nature, purpose and methodology of the study - Able to understand and perform the clinical and neuropsychological evaluations. Specific inclusion criteria depressed suicide attempters: - Subject whose primary psychiatric diagnosis is a major depressive episode according to Diagnostic and Statistical Manual of Mental Disorders -5 (DSM-5) criteria - Personal history of suicide attempt affective controls: - Subject whose primary psychiatric diagnosis is a major depressive episode according to DSM-5 criteria - No personal history of suicide attempt healthy controls: - No personal history of psychiatric disorders (Axis I ) defined by the Mini International Neuropsychiatric Interview (MINI) according to the DSM-5 criteria - No history of suicide attempt Exclusion criteria - Refusal of participation - Deprived of liberty Subject (by judicial or administrative decision) - Subject protected by law (guardianship) - Subject exclusion period in relation to another protocol - Subject is not affiliated to a social security scheme, beneficiary or not such a plan - Subject for which the maximum annual amount of allowances of € 4,500 has been reached - Pregnant women - Breastfeeding Women |
Country | Name | City | State |
---|---|---|---|
France | University Hospital | Montpêllier |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Montpellier | Institut National de la Santé Et de la Recherche Médicale, France, Sys2Diag, Mixt laboratory CNRS/Alcediag, Montpellier |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evolution of the modification of the expression of Adenosine deaminases acting on RNA (ADARs) and of the editing profile of phospho-diesterase 8A (PDE8A) | Studying ADARs expression and RNA editing of genes associated with SB, including PDE8A and comparison of these results between healthy controls and depressed patients with or without history of SB | At the inclusion visit, 3 months and 6 months after the inclusion | |
Secondary | Modification of the expression of ADAR1a enzymes | Comparison of the profiles of ADARs expression and PDE8A editing between non suicidal and suicidal depressed patients and healthy controls | At the inclusion visit, 3 months and 6 months after the inclusion | |
Secondary | Modification of the expression and RNA editing of Spindle And Kinetochore Associated protein 2 (SKA2) | Comparison between non suicidal and suicidal depressed patients and healthy controls | At the inclusion visit, 3 months and 6 months after the inclusion | |
Secondary | Modification of the expression of ADAR1b enzymes | Comparison of the profiles of ADARs expression and PDE8A editing between non suicidal and suicidal depressed patients and healthy controls | At the inclusion visit, 3 months and 6 months after the inclusion | |
Secondary | Modification of the expression of ADAR2 enzymes | Comparison of the profiles of ADARs expression and PDE8A editing between non suicidal and suicidal depressed patients and healthy controls | At the inclusion visit, 3 months and 6 months after the inclusion | |
Secondary | Modification of the expression and RNA editing of Spermidine/Spermine N1-Acetyltransferase 1 (SAT1) | Comparison between non suicidal and suicidal depressed patients and healthy controls | At the inclusion visit, 3 months and 6 months after the inclusion | |
Secondary | Modification of the expression and RNA editing of Interleukins (ILs) | Comparison between non suicidal and suicidal depressed patients and healthy controls | At the inclusion visit, 3 months and 6 months after the inclusion | |
Secondary | Modification of the expression and RNA editing of Chemokines (CXCLs) | Comparison between non suicidal and suicidal depressed patients and healthy controls | At the inclusion visit, 3 months and 6 months after the inclusion | |
Secondary | Modification of the expression and RNA editing of Brain derived Neurotrphic factor (BDNF) | Comparison between non suicidal and suicidal depressed patients and healthy controls | At the inclusion visit, 3 months and 6 months after the inclusion | |
Secondary | Modification of the expression and RNA editing of Cluster of differentiation 24 (CD24) | Comparison between non suicidal and suicidal depressed patients and healthy controls | At the inclusion visit, 3 months and 6 months after the inclusion | |
Secondary | Modification of the expression and RNA editing of Three prime repair exonuclease 1 (TREX1) | Comparison between non suicidal and suicidal depressed patients and healthy controls | At the inclusion visit, 3 months and 6 months after the inclusion | |
Secondary | Modification of the expression and RNA editing of Interferon stimulated gene 15 (ISG15) | Comparison between non suicidal and suicidal depressed patients and healthy controls | At the inclusion visit, 3 months and 6 months after the inclusion | |
Secondary | Modification of the expression and RNA editing of Tumor necrosis factor alpha (TNF alpha) | Comparison between non suicidal and suicidal depressed patients and healthy controls | At the inclusion visit, 3 months and 6 months after the inclusion | |
Secondary | Modification of the expression and RNA editing of Vascular endothelial growth factor (VEGF) | Comparison between non suicidal and suicidal depressed patients and healthy controls | At the inclusion visit, 3 months and 6 months after the inclusion | |
Secondary | Modification of the expression and RNA editing of Hydroxytryptamine receptor 2A (HTR2A) | Comparison between non suicidal and suicidal depressed patients and healthy controls | At the inclusion visit, 3 months and 6 months after the inclusion | |
Secondary | Modification of the expression and RNA editing of insulin-like growth factor protein 7 (IGFB7) | Comparison between non suicidal and suicidal depressed patients and healthy controls | At the inclusion visit, 3 months and 6 months after the inclusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03062150 -
Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression
|
N/A | |
Completed |
NCT04352101 -
Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits
|
Phase 4 | |
Recruiting |
NCT03039387 -
Effects of tDCS on Cognitive Control and Emotion Regulation in Depressed Patients
|
N/A | |
Recruiting |
NCT02213016 -
Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients
|
Phase 4 | |
Completed |
NCT01683539 -
Understanding How Cognitive Remediation Works
|
N/A | |
Completed |
NCT01636791 -
CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care
|
Phase 3 | |
Recruiting |
NCT02237937 -
Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene
|
Phase 4 | |
Completed |
NCT01201148 -
Open Pilot Trial of TES for Depression
|
Phase 2 | |
Completed |
NCT00953108 -
Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients
|
Phase 3 | |
Completed |
NCT00806143 -
Bilateral Versus Monolateral Repetitive Transcranial Stimulation in Depression
|
Phase 4 | |
Terminated |
NCT00695552 -
The Effect of Exercise on Depressive Symptoms in Unmedicated Patients
|
N/A | |
Terminated |
NCT01244711 -
Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines
|
Phase 4 | |
Completed |
NCT00711737 -
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
|
N/A | |
Completed |
NCT00532480 -
Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine
|
Phase 4 | |
Completed |
NCT00482482 -
Yoga in Unipolar and Bipolar Disorders
|
N/A | |
Completed |
NCT00466323 -
The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.
|
N/A | |
Completed |
NCT00616759 -
The Effect on Cognition of Terminating ECT Induced Seizures With Propofol
|
N/A | |
Recruiting |
NCT00209807 -
Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder
|
Phase 4 | |
Completed |
NCT00167310 -
Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
|
Phase 2 | |
Completed |
NCT00149110 -
Chronos: the Use of Chronobiological Treatment in Depression
|
N/A |